NCT04814355
The Effect of Celecoxib on Neuroinflammation in MDD
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Sponsor refiled this as recruiting (was completed)
- Minor Trial status: Active, Not Recruiting to Completed
- Enrollment target: estimated 42 to confirmed 41
- Primary completion date changed from estimate of Feb 2026 to Aug 11, 2025
- Study completion date changed from estimate of Feb 2026 to Feb 28, 2026
- Notable Primary and study completion dates: Jul 31, 2025 to Feb 2026
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary and study completion dates: Jul 31, 2024 to Jul 31, 2025v6
- Notable Primary and study completion dates: Jul 31, 2023 to Jul 31, 2024v5
Show 3 earlier versionsHide 3 earlier versions
- Notable Primary completion date: Jul 31, 2022 to Jul 31, 2023v4
- Minor Secondary endpoint revisedv3
- Minor Secondary endpoint revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in neuroinflammation as measured by [18F]FEPPA PET.
Timeframe: Before and after 8 weeks of treatment with celecoxib.
Secondary (1)
Change in Hamilton Depression Rating Scale-17 (HAMD) score.
Arms and interventions
Celecoxib 400 mgExperimental
Patients will receive 400 mg/day of celecoxib for 8 weeks.
Drugs: Celecoxib 400 mg
Sites
1 site in 1 country
- Psychiatry Department at Stony Brook UniversityStony Brook, New York, United States